Sunshine Biopharma, Inc.

NasdaqCM:SBFM Stock Report

Market Cap: US$5.6m

Sunshine Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SBFM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,0310.102%
Institutions39,5121.98%
General Public1,958,11797.9%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 15474.9%.

Top Shareholders

Top 20 shareholders own 2.08% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
1.72%
Bank of America Corporation, Asset Management Arm
34,475US$95.8k0%no data
0.13%
L1 Capital Pty. Limited
2,643US$7.3k0%no data
0.093%
Altium Capital Management LP
1,864US$5.2k0%no data
0.093%
Malek Chamoun
1,850US$5.1k0%no data
0.025%
Nordwand Advisors, LLC
500US$1.4k0%no data
0.0031%
Steve Slilaty
61US$169.65.17%no data
0.003%
Camille Sebaaly
60US$166.80%no data
0.0029%
Abderrazzak Merzouki
59US$164.01.72%no data
0.0005%
Geode Capital Management, LLC
10US$27.80%no data
0.00035%
National Bank Investments Inc.
7US$19.5133%no data
0.00025%
Merrill Lynch & Co. Inc., Banking Investments
5US$13.90%no data
0.00005%
Securities America Advisors, Inc.
1US$2.80%no data
0.00005%
Fédération des Caisses Desjardins du Québec, Asset Management Arm
1US$2.80%no data
0.00005%
Jaffe Tilchin Investment Partners, LLC
1US$2.80%no data
0.00005%
Toronto-Dominion Bank, Banking Investments
1US$2.80%no data
0.00005%
Morgan Stanley, Investment Banking and Brokerage Investments
1US$2.8-98%no data
0.00005%
Osaic Wealth, Inc. , Asset Management Arm
1US$2.80%no data
0.00005%
Farther Finance Advisors, LLC
1US$2.80%no data
0.00005%
Rise Advisors, Llc , Asset Management Arm
1US$2.80%no data
0.00005%
Rabi Kiderchah
1US$2.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 13:51
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sunshine Biopharma, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David BoucheyAegis Capital Corporation